Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension

Pharmacol Ther. 2023 Apr:244:108389. doi: 10.1016/j.pharmthera.2023.108389. Epub 2023 Mar 20.

Abstract

Right ventricular fibrosis is a stress response, predominantly mediated by cardiac fibroblasts. This cell population is sensitive to increased levels of pro-inflammatory cytokines, pro-fibrotic growth factors and mechanical stimulation. Activation of fibroblasts results in the induction of various molecular signaling pathways, most notably the mitogen-activated protein kinase cassettes, leading to increased synthesis and remodeling of the extracellular matrix. While fibrosis confers structural protection in response to damage induced by ischemia or (pressure and volume) overload, it simultaneously contributes to increased myocardial stiffness and right ventricular dysfunction. Here, we review state-of-the-art knowledge of the development of right ventricular fibrosis in response to pressure overload and provide an overview of all published preclinical and clinical studies in which right ventricular fibrosis was targeted to improve cardiac function.

Keywords: Fibrosis; Myocardial stiffness; Right ventricle; Therapy, cardiac fibroblast; Ventricular dysfunction.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Fibroblasts / metabolism
  • Fibrosis
  • Heart Failure*
  • Heart Ventricles / metabolism
  • Heart Ventricles / pathology
  • Humans
  • Hypertension, Pulmonary* / etiology
  • Myocardium / metabolism
  • Ventricular Remodeling